share_log

浙江滬杭甬:截至 2024 年 11 月 30 日股份發行人的證券變動月報表

ZHEJIANGEXPRESS: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 November, 2024

HKEX ·  03:40

Summary by Moomoo AI

截至2024年11月30日,浙江沪杭甬的法定和註冊股本保持不變,H股和內資股的已發行股份數量分別為1,979,021,737股和4,014,778,800股。公司確認在本月內未有新增或減少已發行股份及庫存股份,並遵循所有適用的上市規則和法律規定。公司秘書鄭輝確認,所有證券發行或庫存股份的出售或轉讓均已獲得董事會授權批准,並已履行所有必要的法律和監管要求。
截至2024年11月30日,浙江沪杭甬的法定和註冊股本保持不變,H股和內資股的已發行股份數量分別為1,979,021,737股和4,014,778,800股。公司確認在本月內未有新增或減少已發行股份及庫存股份,並遵循所有適用的上市規則和法律規定。公司秘書鄭輝確認,所有證券發行或庫存股份的出售或轉讓均已獲得董事會授權批准,並已履行所有必要的法律和監管要求。
As of November 30, 2024, the statutory and registered share capital of Zhejiang-Hangzhou-Ningbo remained unchanged, with the number of H shares and domestic shares issued being 1,979,021,737 shares and 4,014,778,800 shares respectively. The company confirms that there has been no addition or reduction of issued shares and treasury shares this month, and it complies with all applicable listing rules and legal requirements. The company secretary Zheng Hui confirms that all securities issuance or transfer of treasury shares have been authorized and approved by the board of directors and have complied with all necessary legal and regulatory requirements.
As of November 30, 2024, the statutory and registered share capital of Zhejiang-Hangzhou-Ningbo remained unchanged, with the number of H shares and domestic shares issued being 1,979,021,737 shares and 4,014,778,800 shares respectively. The company confirms that there has been no addition or reduction of issued shares and treasury shares this month, and it complies with all applicable listing rules and legal requirements. The company secretary Zheng Hui confirms that all securities issuance or transfer of treasury shares have been authorized and approved by the board of directors and have complied with all necessary legal and regulatory requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more